Scribe Therapeutics
Sean Higgins has been employed in the scientific field since 2013. Sean began their career as a PhD Candidate in Molecular and Cell Biology at the University of California, Berkeley. In 2018, they joined Scribe Therapeutics as a Scientist.
Sean Higgins received a Bachelor of Science in Biochemistry from the University of Washington in 2013. Sean then went on to pursue a Doctor of Philosophy in Biochemistry and Molecular Biology from the University of California, Berkeley, which they completed in 2018.
This person is not in the org chart
Scribe Therapeutics
1 followers
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.